TJO-087 is under clinical development by TaeJoon Pharmaceuticals and currently in Phase III for Keratoconjunctivitis Sicca (Dry Eye). According to GlobalData, Phase III drugs for Keratoconjunctivitis Sicca (Dry Eye) have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how TJO-087’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TJO-087 overview

TJO-087 (cyclosporine) is under development for the treatment of dry eye syndrome. The drug candidate is administered topically as eye drops and it acts by targeting calcineurin.

TaeJoon Pharmaceuticals overview

TaeJoon Pharmaceuticals (Taejoon) is a pharmaceutical company that markets ophthalmic agents and other drugs. It offers products in the form of injections, powders, eye drops, spray, syrups, tablets, soft capsules, liquids for external use, and hard capsules. The company’s powder products comprise of coolprep powder, polyethylen glycol, and colyte powder products. Taejoon’s products are used in ophthalmological, laxative, gastrointestinal, and contrast media applications. It sells products through a network of distributors in South Korea, Thailand, Germany, Russia, the UK and the US. The company operates in Seoul, Gunpo, Daejeon, Daegu, Gwangju and Busan, South Korea. Taejoon is headquartered in Seoul, South Korea.

For a complete picture of TJO-087’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.